This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House
TheStreet Rating

10 Best Healthcare Equipment Stocks for 2015

Top Rated Stocks

Every day TheStreet Ratings produces a list of the top rated stocks. These 10 healthcare equipment stocks are rated highest by TheStreet Ratings' value-focused stock rating model.

Equity Top: Healthcare Equipment


Source: TheStreet Ratings

Best Investments for 2015

Healthcare Equipment

In April, Celladon is expecting results from a mid-stage study of a gene therapy aiming to improve the pumping ability of the heart in patients with advanced heart failure.
3/25/15 10:06AM
Ocular hasn't conducted clinical trials that would demonstrate that OTX-DP is any better than eye drops in reducing swelling and pain in the eye.
3/10/15 10:17AM
The Securities and Exchange Commission's top cop wants drug companies to be more transparent with investors about their dealings with the U.S. Food and Drug Administration.
3/4/15 1:08PM
Biotech columnist Adam Feuerstein answers readers' questions about health care.
1/23/15 6:00AM
The timing of the Afrezza commercial launch is still a mystery following Sanofi's presentation.
1/12/15 1:35PM
Good calls: Vertex, InterMune, Chelsea, Galena, Exact Sciences. The bad calls: Avanir, Amarin, Exelixis and the bursting biotech stock bubble.
12/19/14 9:02AM
Biotech columnist Adam Feuerstein answers readers' questions about health care.
12/5/14 6:00AM
Biotech columnist Adam Feuerstein answers readers' questions about health care.
11/21/14 6:00AM
Not everyone is convinced that the new Sanofi CEO will remain committed to MannKind and its inhaled insulin Afrezza.
11/4/14 1:40PM
Biotech columnist Adam Feuerstein answers readers' questions about health care.
10/17/14 7:05AM
Even in biotech where the "blue sky" potential for experimental drugs so often sends stock prices soaring, no company can escape the gravitational pull of balance sheets and income statements.
8/13/14 12:04PM
For all the hype about Afrezza's greatness, Mann walks away with a joint venture in which he secures just one-third of Afrezza's potential profit -- and losses.
8/11/14 6:49AM
AcelRx believes it can gather all the requested information and re-submit Zalviso to the FDA before the end of the year.
7/28/14 9:44AM
MannKind must report second-quarter financials before the end of the second week in August, which sets a quasi-deadline for Afrezza partner plans.
7/25/14 11:30AM
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
7/18/14 7:51AM

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV

Markets

DOW 17,678.23 -40.31 -0.23%
S&P 500 2,056.15 -4.90 -0.24%
NASDAQ 4,863.3620 -13.1570 -0.27%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs